Trial Profile
Phase II trial − Weekly Taxotere [docetaxel] and topotecan for recurrent ovarian, primary peritoneal, endometrial and uterine cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Topotecan (Primary)
- Indications Endometrial cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
- Focus Therapeutic Use
- 13 Nov 2005 New trial record.